Please login to the form below

Not currently logged in
Email:
Password:

Inovio appoints Adel Mahmoud to board of directors

Former president of Merck Vaccines will advise on development of synthetic vaccines at US company

Adel Mahmoud - InovioInovio Pharmaceuticals has appointed former president of Merck Vaccines Dr Adel Mahmoud to its board of directors.

Dr Mahmoud spent six years in his vaccines position at Merck from 1999 to 2005, overseeing the development of human papillomavirus (HPV) vaccine Gardasil, one of the first vaccines developed to protect against cervical cancer.

Other vaccines developed during Mahmoud's time at Merck include Zostavax for shingles, Proquad for measles, mumps, rubella and chicken pox, and Rotateq, which protects against the rotavirus.

Dr J Joseph Kim, president and CEO of US-based Inovio, said: "Dr Mahmoud is known throughout the industry for his success in gaining approval for several blockbuster vaccines.  His insights will be advantageous to Inovio as we move our synthetic vaccine portfolio toward late-stage clinical trials."

This includes vaccines currently in development for cervical dysplasia, leukaemia, hepatitis C virus, influenza and HIV.

Dr Mahmoud is currently professor of the department of molecular biology and the Woodrow Wilson School of Public and International Affairs at Princeton University.

He has also helped with strategy development for global health agencies tackling bioterrorism and emerging diseases such as pandemic influenza and SARS.

Before joining Merck, Dr Mahmoud served as chair of the department of medicine and physician-in-chief at Case Western Reserve University School of Medicine and University Hospitals of Cleveland.

28th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics